Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 31;12(2):180–188. doi: 10.1111/cts.12604

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Pfizer Inc. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Analysis of biomarkers by hydroxyurea (HU) use and fetal hemoglobin (HbF) levels. (a) Box and whiskers plot of HbF baseline levels (%) in patients (n = 27) with and without HU treatment. Boxes present area between 25th and 75th percentile values. Whiskers extend 1.5 of interquartile range from the box. Line within each box is the median value. The circles represent individual observations that could be considered outliers. (b) The percent changes from baseline at day 29 for biomarkers in subgroups of patients (PF‐04447943 25 mg twice daily), with vs. without HU cotreatment, and low vs. high baseline HbF levels. Low HbF levels were defined as < 10%, and high baseline HbF levels were 10% or higher, based on median of the sample distribution. Forest plot presents estimates and 95% confidence intervals, based on repeated measures model.